Security record · archived quarter
OLMA
Olema Pharmaceuticals, Inc. · Healthcare · Biotechnology
12Tracked holders
0Δ holders
11.47MShares held
$66.81MReported value
+0New positions
−0Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +19.0% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | -5 | 48.00M | $600.59M | +5 | −10 |
| Q1 2026 | 85 | +7 | 50.63M | $755.34M | +15 | −8 |
| Q4 2025 | 78 | +3 | 39.80M | $995.19M | +3 | — |
| Q3 2025 | 16 | 0 | 15.07M | $147.57M | +1 | −1 |
| Q2 2025 | 13 | -1 | 13.76M | $58.63M | — | −1 |
| Q1 2025 | 11 | -1 | 8.23M | $30.93M | +1 | −2 |
| Q4 2024 | 12 | 0 | 11.47M | $66.81M | — | — |
| Q3 2024 | 11 | 0 | 7.78M | $92.93M | +1 | −1 |
| Q2 2024 | 11 | — | 6.52M | $70.59M | — | — |
Who holds it · Q4 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 3.67M | -0.5% | $21.40M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 1.86M | — | $10.83M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 1.68M | +34.4% | $9.81M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 1.68M | +34.4% | $9.81M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.53M | +52.1% | $8.84M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.53M | +52.1% | $8.84M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 1.53M | +52.1% | $8.84M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 1.53M | +52.1% | $8.84M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Millennium Management ✦ | 979.22K | +1154.4% | $5.71M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 926.16K | -0.9% | $5.40M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 926.16K | -0.9% | $5.40M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 365.20K | -8.7% | $2.13M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | Marshall Wace ✦ | 192.94K | -19.7% | $1.12M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Marshall Wace ✦ | 192.94K | -19.7% | $1.12M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 157.30K | +435.0% | $917,059 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 72.88K | -27.2% | $424,873 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 26.11K | -17.0% | $153,000 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 12.45K | -51.4% | $72,554 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 200.00K shares, $10,000 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q4 2024 ·
Methodology ·
Get this via the API